What is Biodesix?
Biodesix, Inc. operates at the intersection of biotechnology and data science, specializing in blood-based diagnostic solutions that address critical gaps in lung cancer management. By leveraging advanced molecular diagnostics, the company provides physicians with actionable insights to assess malignancy risk and guide personalized treatment pathways. Its core offerings, such as the Nodify XL2 and Nodify CDT tests, are designed to streamline the clinical decision-making process, while its genomic profiling tools, including GeneStrat ddPCR and NGS, offer deep insights into tumor mutations and immune system states. This integrated approach positions Biodesix as a vital partner for oncology practices seeking to improve patient outcomes through precision medicine.
How much funding has Biodesix raised?
Biodesix has raised a total of $268.4M across 11 funding rounds:
Series C
$7.1M
Series D
$20M
Series E
$38M
Series F
$22M
Debt
$23M
Debt
$2M
Stock Offering
$72M
Stock Offering
$16.3M
Stock Offering
$50M
Series C (2010): $7.1M, investors not publicly disclosed
Series D (2011): $20M, investors not publicly disclosed
Series E (2015): $38M, investors not publicly disclosed
Series F (2016): $22M, investors not publicly disclosed
Debt (2018): $23M led by Innovatus Capital Partners
Debt (2020): $2M supported by PPP
Stock Issuance/Offering (2020): $72M featuring Undisclosed
Stock Issuance/Offering (2022): $16.3M, investors not publicly disclosed
Stock Issuance/Offering (2022): $50M with participation from Lincoln Park Capital
Key Investors in Biodesix
Lincoln Park Capital
Lincoln Park Capital is a Chicago-based investment group and asset management firm that specializes in opportunistic investing across public and private companies, real estate, and various money management strategies.
Innovatus Capital Partners
Innovatus Capital Partners specializes in long-term capital investments across various asset classes, focusing on opportunities created by market volatility and disruptions.
Undisclosed Investors
What's next for Biodesix?
Looking ahead, Biodesix is well-positioned to leverage its recent capital injection to accelerate the commercial adoption of its diagnostic suite. The company's strategic focus remains on enhancing the clinical utility of its blood-based tests, which are essential for reducing unnecessary invasive procedures and optimizing therapeutic interventions. As the diagnostic landscape shifts toward more personalized, non-invasive methodologies, Biodesix's ability to integrate complex genomic data into routine clinical workflows will be a key driver of its long-term value proposition. Investors will likely monitor the company's progress in expanding its market reach and its ability to maintain a competitive edge in the rapidly evolving field of molecular diagnostics.
See full Biodesix company page
